Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients.
Sekino Y, Imajo K, Sakai E, Uchiyama T, Iida H, Endo H, Hosono K, Sakamoto Y, Fujita K, Yoneda M, Takahashi H, Koide T, Tokoro C, Abe Y, Saito S, Maeda S, Gotoh E, Takihata M, Terauchi Y, Nakajima A, Inamori M. Sekino Y, et al. Among authors: takihata m. Intern Med. 2011;50(21):2449-55. doi: 10.2169/internalmedicine.50.5672. Epub 2011 Nov 1. Intern Med. 2011. PMID: 22041341 Free article.
Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, Nagakura M, Kawasaki S, Akema N, Hasegawa M, Nakajima S, Shinoda K, Toumura S, Tsunoda S, Enomoto H, Shimotomai H, Terauchi Y. Masuda K, et al. Among authors: takihata m. Expert Opin Pharmacother. 2013 Jun;14(9):1111-8. doi: 10.1517/14656566.2013.790365. Epub 2013 Apr 22. Expert Opin Pharmacother. 2013. PMID: 23600363 Clinical Trial.
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: takihata m. J Clin Med Res. 2016 Feb;8(2):116-25. doi: 10.14740/jocmr2417w. Epub 2015 Dec 28. J Clin Med Res. 2016. PMID: 26767080 Free PMC article.
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: takihata m. J Clin Med Res. 2016 Mar;8(3):267. doi: 10.14740/jocmr2417wc1. Epub 2016 Jan 26. J Clin Med Res. 2016. PMID: 26858805 Free PMC article.
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iemitsu K, et al. Among authors: takihata m. J Clin Med Res. 2016 May;8(5):373-8. doi: 10.14740/jocmr2492w. Epub 2016 Mar 20. J Clin Med Res. 2016. PMID: 27081422 Free PMC article.
27 results